ABTD
REGN icon

Arvest Bank Trust Division’s Regeneron Pharmaceuticals REGN Stock Holding History

Arvest Bank Trust Division’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Sell
358
-130
-27% -$88.5K 0.01% 230
2026
Q1 		$377K Buy
+488
New +$374K 0.02% 172

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arvest Bank Trust Division's REGN Position: Q2 2026 in Review

Arvest Bank Trust Division reduced its Regeneron Pharmaceuticals (REGN) stake by 27% in Q2 2026, selling an estimated $88.5K and leaving 358 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #230.

Arvest Bank Trust Division first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $377K in Q1 2026. 1,339 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arvest Bank Trust Division held 358 shares of Regeneron Pharmaceuticals worth $223K as of Q2 2026.
  • Arvest Bank Trust Division sold 130 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $88.5K.
  • Regeneron Pharmaceuticals made up 0.01% of Arvest Bank Trust Division's portfolio in Q2 2026, its #230 holding.
  • Arvest Bank Trust Division first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Arvest Bank Trust Division's Regeneron Pharmaceuticals position peaked at $377K in Q1 2026.
  • 1,339 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arvest Bank Trust Division's 13F filing for Q2 2026, filed 13 Aug 2026.